Amylyx Pharmaceuticals, Inc. $AMLX Shares Sold by Perceptive Advisors LLC

Perceptive Advisors LLC trimmed its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 7.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 8,284,882 shares of the company’s stock after selling 667,483 shares during the quarter. Amylyx Pharmaceuticals comprises approximately 1.8% of Perceptive Advisors LLC’s holdings, making the stock its 15th largest holding. Perceptive Advisors LLC owned about 0.08% of Amylyx Pharmaceuticals worth $100,081,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Meeder Asset Management Inc. acquired a new stake in Amylyx Pharmaceuticals during the 4th quarter valued at approximately $25,000. Aster Capital Management DIFC Ltd acquired a new stake in Amylyx Pharmaceuticals during the 3rd quarter valued at approximately $48,000. California State Teachers Retirement System acquired a new stake in Amylyx Pharmaceuticals during the 2nd quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd lifted its stake in Amylyx Pharmaceuticals by 1,116.9% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,454 shares of the company’s stock valued at $54,000 after acquiring an additional 4,088 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Amylyx Pharmaceuticals by 54.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company’s stock valued at $64,000 after acquiring an additional 1,890 shares during the period. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AMLX has been the subject of several research reports. Bank of America lifted their price objective on shares of Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Wall Street Zen cut shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Mizuho boosted their target price on shares of Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the company an “outperform” rating in a research note on Tuesday, April 28th. Guggenheim boosted their target price on shares of Amylyx Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 19th. Finally, Stifel Nicolaus started coverage on shares of Amylyx Pharmaceuticals in a research note on Tuesday, March 3rd. They issued a “buy” rating and a $21.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $23.00.

Amylyx Pharmaceuticals Price Performance

AMLX opened at $15.25 on Thursday. The firm has a fifty day moving average price of $15.15 and a 200 day moving average price of $14.27. Amylyx Pharmaceuticals, Inc. has a 1 year low of $4.80 and a 1 year high of $18.60. The stock has a market cap of $1.70 billion, a P/E ratio of -10.17 and a beta of -0.16.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.03). Equities analysts expect that Amylyx Pharmaceuticals, Inc. will post -1.4 EPS for the current year.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.